Rhythm Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. 

CEO
David P. Meeker
CEODavid P. Meeker
Employees
414
Employees414
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
2008
Founded2008
Employees
414
Employees414

RYTM Key Statistics

Market cap
7.07B
Market cap7.07B
Price-Earnings ratio
-32.95
Price-Earnings ratio-32.95
Dividend yield
Dividend yield
Average volume
416.38K
Average volume416.38K
High today
$105.71
High today$105.71
Low today
$101.25
Low today$101.25
Open price
$103.53
Open price$103.53
Volume
458.33K
Volume458.33K
52 Week high
$122.20
52 Week high$122.20
52 Week low
$74.50
52 Week low$74.50

Stock Snapshot

Rhythm Pharmaceuticals(RYTM) stock is priced at $102.74, giving the company a market capitalization of 7.07B. It carries a P/E multiple of -32.95.

During the trading session on 2026-09-06, Rhythm Pharmaceuticals(RYTM) shares reached a daily high of $105.71 and a low of $101.25. At a current price of $102.74, the stock is +1.5% higher than the low and still -2.8% under the high.

Trading activity shows a volume of 458.33K, compared to an average daily volume of 416.38K.

Over the past 52 weeks, Rhythm Pharmaceuticals(RYTM) stock has traded between a high of $122.20 and a low of $74.50.

Over the past 52 weeks, Rhythm Pharmaceuticals(RYTM) stock has traded between a high of $122.20 and a low of $74.50.

RYTM News

Benzinga 4d
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga

...

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Simply Wall St 7d
Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ Narrative

Rhythm Pharmaceuticals has received marketing authorization in Japan for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity, the first approved the...

Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ Narrative

Analyst ratings

89%

of 18 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.